Press release

Helix Expands Focus to Population Health Solutions and Appoints Illumina Veteran Marc Stapley as CEO

SAN CARLOS, Calif., April 25, 2019 /PRNewswire/ -- Helix today announced it is broadening its market focus to include health systems, payers and researchers

articleIllumina, Inc.April 25, 20193/company/illumina-inc/news/helix-expands-focus-population-health-solutions-and-appoints-illumina-veteran-marc
Helix Expands Focus to Population Health Solutions and Appoints Illumina Veteran Marc Stapley as CEO

About this update from Illumina, Inc.

[{"type":"text","content":"SAN CARLOS, Calif., April 25, 2019 /PRNewswire/ -- Helix today announced it is broadening its market focus to include health systems, payers and researchers who are interested in sequencing large population cohorts. Helix will be offering those partners its population health solutions, a suite of sequencing products and services built around the Helix proprietary Exome+™ assay, packaged with its workflow, CLIA/CAP lab, return of results platform and data capabilities. To lead this expansion, the company has named Marc Stapley as Chairman and CEO. \n\"While we are announcing a new strategic business focus today, Helix's mission remains unchanged: to empower every person to improve their life through DNA,\" said Marc Stapley, Helix CEO. \"Our turnkey population health solutions enable institutions to quickly scale projects that engage communities and accelerate translational research and discovery, ultimately allowing every person to benefit from the power of their genome.\" \nStapley has been a member of Helix's Board of Directors since the company was founded four years ago, and is a seven-year veteran of Illumina, where he served as Chief Administrative Officer, Chief Financial Officer and from 2017–2018 oversaw the company's population genomics team. Prior to Illumina, he held executive finance positions at Pfizer and other large multinational companies.\n\"The Helix team, led by Robin Thurston, has succeeded in creating engaging genomics offerings, supported by a world-class CLIA/CAP laboratory and assay,\" said Jay Flatley, Executive Chairman of Illumina. \"I'd like to thank Robin for his leadership of Helix over the last three years, and welcome Marc as the incoming CEO. It is gratifying to see the business enter a new phase where Helix's technology and market knowledge will be leveraged to drive a new era where genomics is part of everyone's personal health record.\"\nHelix's population health solutions have already seen success in partnership with Renown IHI as part of the Healthy Nevada program. \"Helix sequenced 40,000 Nevadans for us in record time, and the company's consumer-facing engagement tools are key to helping us expand to 250,000 Nevadans in the fastest-growing population health project in the world,\" said Anthony Slonim, M.D., DrPH, FACHE, president and CEO of Renown Health and president of Renown Institute ...

More updates from Illumina, Inc.